OVERVIEW OF WGNV 

The Working Group on New TB Vaccines (WGNV) was established in 2001. It is one of the nine Working Groups of the Stop TB Partnership. 

The mission of the WGNV is to facilitate research and development (R&D) of new TB vaccines by providing an inclusive forum for stakeholders to engage in scientific exchange, foster discussion, and advocate for greater support and investment in TB vaccine R&D. 

The WGNV is an informal network of stakeholders engaged in all aspects of TB vaccine R&D and from all constituencies, including academics, product developers, clinicians, advocates, and affected communities. Membership is open to anyone interested in being engaged and involved in TB vaccine R&D. 

OVERVIEW AND EXPECTATIONS OF WGNV CORE GROUP 

The WGNV Core Group (CG) is responsible for ensuring the effectiveness of the WGNV by setting strategic direction, identifying priority areas of work, and engaging in WGNV activities. CG members are the foundation of the WGNV and must be willing/able to devote time to WGNV activities. 

The CG is expected to: 

• Oversee and engage in the activities of WGNV 

• Monitor progress of WGNV activities 

• Assist WGNV Chair in addressing strategic and operational issues 

• Actively participate in at least one WGNV activity/priority per grant year 

• Meet regularly as required, primarily by videoconference 

• Collaborate with and consult other Stop TB WGs, Partnership Secretariat, and partners on cross-cutting issues 

• Serve as an independent, technical, expert advisory group where required by the Stop TB Partnership and partners 

• Be able to work and communicate in written and spoken English 

• Have regular access to internet and email service 

All Core Group members should demonstrate the following: 

• Experience working in partnerships 

• Ability to be an effective representative of their constituency group in WGNV discussions, activities, and planning 

• Commitment to increasing the visibility of TB vaccine R&D in the overall TB and public health agenda 

• Willingness and ability to play a leadership role in developing and advancing the activities strategies of the WGNV that fall within their area(s) of expertise 

 WGNV CG members are expected to contribute a minimum of two (2) hours per month, although actual time per month will vary based on activities. This time is not compensated. 

An actively engaged Core Group is essential to the success of the WGNV. If a Core Group member is no longer able to fulfill their commitments, they should notify the WGNV Secretariat of their intent to resign from their position. If a Core Group member is determined by the Chair and Secretariat not to be regularly engaging in calls and WGNV activities, the member may be asked to relinquish their position on the Core Group.   

Private Sector Representative 

The Private Sector Representative to the WGNV Core Group brings the perspective of the private sector to Core Group discussions, encourages private sector membership and participation in WGNV, and helps WGNV engage private sector entities in its activities and programs.  

The term for this position is two years. 

In addition to the expectations of all Core Group members as noted above, the Private Sector Representative should meet the following additional criteria: 

• Affiliated with a company that is engaged in TB vaccine research and development 

• Holds a position within the company with responsibilities that are focused on or support TB vaccine research and development 

• Willingness and ability to assist WGNV in engaging with private sector companies to share information and resources, and to expand private sector membership and engagement in WGNV 

To apply: 

Representatives from the private sector interested in being considered for this position on the WGNV Core Group should submit their CV and a letter of interest via the WGNV website by 28 February 2026. 

Applications will be reviewed by the WGNV Core Group, which will select the Private Sector Representative. 

Click here to apply.